01 6Olmesartan
02 3Olmetec
03 1Olmetec / Olmetec Plus/ Sevikar / Sevikar Hct / Benicar/ Benicar Hct / Azor / Tribenzor
04 4Rezaltas
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 85
2019 Revenue in Millions : 96
Growth (%) : -11
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 88
2019 Revenue in Millions : 113
Growth (%) : -22
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 123
2019 Revenue in Millions : 137
Growth (%) : -11
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 219
2019 Revenue in Millions : 214
Growth (%) : 2
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 104
2020 Revenue in Millions : 122
Growth (%) : -8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 217
Growth (%) : -15
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 155
2021 Revenue in Millions : 171
Growth (%) : -9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 134
2022 Revenue in Millions : 155
Growth (%) : -2
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 648
2016 Revenue in Millions : 536
Growth (%) : 21
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 1,242
2017 Revenue in Millions : 608
Growth (%) : 104%
LOOKING FOR A SUPPLIER?